The present invention pertains to quantum-scale biocidal particles and chemical reactions that disrupt and eviscerate microbial matter by combining aqueous and dry components. As halo-fullerene activation requires volatile excitation to mix, contact and collide so as to rupture microbial matter, atomic scale chemical reactions impart the requisite movement of engineered halo-fullerenes to destroy bacterial, fungal and viral matter upon contact. The present invention includes two primary mechanisms: an excitation chemistry and biocidal, hydrophobic halo-fullerenes. Upon aqueous exposure, the dry composition initiates a chemical reaction that activates biocidal halo-fullerenes to disrupt biologic surfaces in topical applications. The object of the present invention is a shelf stable, pre-packaged wiping material or dry packet for rehydration with broad spectrum antimicrobial activity. In one example, a matrix or wipe material would be comprised of densely packed and highly concentrated halo-fullerenes and a chemical reaction stimulant. When activated upon aqueous exposure, it would relax water molecules, alter hydrogen binding, and disrupt adhesion and cohesion forces that characterize surface tensions. These dynamics would then isolate sebaceous substances and free oxygen radicals, along with outgassing of carbon dioxide. The chemical reaction stimulant thus transfers energy and hyperactivates otherwise inert halo-fullerenes to form a biocidal composition. Broader utilities range from topical cleansing for personal hygiene, as well as various clinical and surgical procedures, as surgical and prophylactic lavage and rinse solutions, and enteral formulations as a hypertonic renal flush combined with short-acting diuresis. The halo-fullerene and hypertonic renal flush would cause osmotic cellular outflow, mitigate cellular microbial uptake and initial seroconversion and bloodborne events, while a botanical diuretic agent would facilitate systemic prophylaxis or treatment of UTIs.

The present invention provides a novel substance that promotes expression of filaggrin gene involved in improvement of the moisture retention function of skin. The inventors of the present invention found that expression of filaggrin gene fluctuates rhythmically over a roughly 24 hour cycle, screened candidate substances based on the time at which expression reaches a maximum following addition of the candidate substance, and identified zanthoxylum extract, 3-(1′-piperidine)propionic acid, geranium oil, cypress oil, rose oil, galvanum oil, pepper oil, basil oil, methyl-o-toluate, methyl anthranilate and dimethyl anthranilate as filaggrin gene expression promoting agents.

The present invention provides a novel substance that promotes expression of filaggrin gene involved in improvement of the moisture retention function of skin. The inventors of the present invention found that expression of filaggrin gene fluctuates rhythmically over a roughly 24 hour cycle, screened candidate substances based on the time at which expression reaches a maximum following addition of the candidate substance, and identified zanthoxylum extract, 3-(1′-piperidine)propionic acid, geranium oil, cypress oil, rose oil, galvanum oil, pepper oil, basil oil, methyl-o-toluate, methyl anthranilate and dimethyl anthranilate as filaggrin gene expression promoting agents.

A method to prepare a therapeutic balm is disclosed. A first phase solution is prepared in an oak barrel using a grain neutral spirit. The first phase is mixed for 10 minutes per day for a month to prepare a second phase solution. The second phase solution is filtered at least twice to prepare a filtrate. The filtrate and third phase components are mixed to prepare a third phase solution. The third phase solution is mixed with a distilled wine liquor to prepare a fourth phase solution. The fourth phase solution is mixed at least twice a day for a month to prepare a fifth phase solution. The fifth phase solution is mixed with cranberry juice, pomegranate juice, and raspberry juice to prepare a sixth phase solution. The sixth phase solution is stored in a ceramic bottle for a least six months at room temperature to prepare a therapeutic balm.

A method to prepare a therapeutic balm is disclosed. A first phase solution is prepared in an oak barrel using a grain neutral spirit. The first phase is mixed for 10 minutes per day for a month to prepare a second phase solution. The second phase solution is filtered at least twice to prepare a filtrate. The filtrate and third phase components are mixed to prepare a third phase solution. The third phase solution is mixed with a distilled wine liquor to prepare a fourth phase solution. The fourth phase solution is mixed at least twice a day for a month to prepare a fifth phase solution. The fifth phase solution is mixed with cranberry juice, pomegranate juice, and raspberry juice to prepare a sixth phase solution. The sixth phase solution is stored in a ceramic bottle for a least six months at room temperature to prepare a therapeutic balm.

A method to prepare a therapeutic balm is disclosed. A first phase solution is prepared in an oak barrel using a grain neutral spirit. The first phase is mixed for 10 minutes per day for a month to prepare a second phase solution. The second phase solution is filtered at least twice to prepare a filtrate. The filtrate and third phase components are mixed to prepare a third phase solution. The third phase solution is mixed with a distilled wine liquor to prepare a fourth phase solution. The fourth phase solution is mixed at least twice a day for a month to prepare a fifth phase solution. The fifth phase solution is mixed with cranberry juice, pomegranate juice, and raspberry juice to prepare a sixth phase solution. The sixth phase solution is stored in a ceramic bottle for a least six months at room temperature to prepare a therapeutic balm.

Disclosed are compositions containing an extract of Serenoa repens, a lipophilic extract of Zingiber officinalis and a lipophilic extract of Echinacea angustifolia or Zanthoxylum bungeanum.

Compositions containing natural and botanical extracts for use in inhibiting one, two, or three of (a)-(c): (a) demethylation of PP2A by PME-1 methylesterase; (b) formation of free radicals and reactive oxygen species; and/or (c) inflammation. These compositions include an extract of one or more botanicals selected from the group consisting of: juniper berry fruit, schisandra fruit, strawberry fruit, avocado seeds, black raspberry seeds, blueberry seeds, celery seeds, cranberry seeds, fennel seeds, grape seeds, guarana seeds, red raspberry seeds, maca root, goldenseal root, turmeric root, magnolia bark, pygeum bark, red raspberry leaf, almond, cocoa powder, Echinacea angustifolia, prickly pear cactus and walnut.

Compositions containing natural and botanical extracts for use in inhibiting one, two, or three of (a)-(c): (a) demethylation of PP2A by PME-1 methylesterase; (b) formation of free radicals and reactive oxygen species; and/or (c) inflammation. These compositions include an extract of one or more botanicals selected from the group consisting of: juniper berry fruit, schisandra fruit, strawberry fruit, avocado seeds, black raspberry seeds, blueberry seeds, celery seeds, cranberry seeds, fennel seeds, grape seeds, guarana seeds, red raspberry seeds, maca root, goldenseal root, turmeric root, magnolia bark, pygeum bark, red raspberry leaf, almond, cocoa powder, Echinacea angustifolia, prickly pear cactus and walnut.

A medicine developed for treatment of psoriasis and production method thereof are disclosed. This medicine for treatment of psoriasis developed in the scope of the present invention comprises tallow, larch resin, beeswax, gum mastic, propolis, Alkanna tinctoria, alum and Juniper tar. The production method of the psoriasis medicine of the present invention includes the steps of: Melting the tallow at 300° C. by continuously mixing it with the beeswax, adding first the gum mastica and then the propolis to the obtained molten mixture, adding ground larch resin to the mixture together with alum, finally adding ground Alkanna tinctoria and juniper tar to the mixture, obtaining a homogenous mixture by means of continuous mixing, filtering the homogenous mixture, obtaining the medicine for treatment of psoriasis, which is the final product in the form an elute.